PUBLISHER: DelveInsight | PRODUCT CODE: 1226647
PUBLISHER: DelveInsight | PRODUCT CODE: 1226647
"ACTEMRA Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ACTEMRA for Rheumatoid Arthritis in the 7MM. A detailed picture of the ACTEMRA for Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the ACTEMRA for Rheumatoid Arthritis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ACTEMRA market forecast, analysis for Rheumatoid Arthritis in the 7MM, descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about emerging therapies in Rheumatoid Arthritis.
ACTEMRA (known as RoActemra in Europe) is a first-in-class anti-IL-6 receptor (aIL-6R) therapy developed by Roche and Chugai. Tocilizumab blocks the inflammatory protein IL-6. IL-6 is believed to play a key role in activating the inflammatory pathway that contributes to the signs and symptoms of Rheumatoid Arthritis (RA) and other inflammatory autoimmune conditions. ACTEMRA binds to IL-6 receptors, blocking the pro-inflammatory effect of IL-6 cytokines and improvIng joint pain and swelling from arthritis and other symptoms caused by inflammation.
ACTEMRA (Tocilizumab) is a biologic medication currently approved to treat adults with moderately to severely active RA, adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Biologic medications are proteins designed by humans that affect the immune system.
Actemra may be used as monotherapy or concomitantly with methotrexate or other non-biologic DMARDs as an intravenous infusion or a subcutaneous injection.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
ACTEMRA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of ACTEMRA in Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of ACTEMRA for Rheumatoid Arthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions